UK study tracks migraine Drug's speed in Real-World use
NCT ID NCT06898047
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study follows 250 UK adults with migraine who already use rimegepant for acute attacks. Over 12 weeks, participants complete daily surveys to report how quickly the drug provides meaningful pain relief and eases other symptoms. The goal is to understand consistency of response in everyday life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
London, United Kingdom
Conditions
Explore the condition pages connected to this study.